MX2009000950A - Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos. - Google Patents

Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.

Info

Publication number
MX2009000950A
MX2009000950A MX2009000950A MX2009000950A MX2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A
Authority
MX
Mexico
Prior art keywords
glucocorticoid receptor
mammalian subject
treatment
infectious conditions
receptor antagonists
Prior art date
Application number
MX2009000950A
Other languages
English (en)
Inventor
B W M M Bernardus Peeters
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2009000950A publication Critical patent/MX2009000950A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona el uso de un antagonista del receptor de glucocorticoide para la manufactura de un medicamento para el estímulo inmune, tal como la prevención o tratamiento de infecciones o condiciones infecciosas, en un sujeto mamífero de edad avanzada, un sujeto mamífero con bajos valores de suero DHEAS, un sujeto mamífero con una alta proporción en suero de cortisol/DHEAS, o un sujeto mamífero con cuentas altas de neutrófilos. En particular el antagonista del receptor de glucocorticoide puede ser seleccionado del grupo consistente de un derivado de dibenzopiranil definido y/o ejemplificado en la Patente Norteamericana US 6329534 y el documento WO2001116128, mifepristona, y (11ß, 17ß)-11-(1,3-benzodioxol-5-il)-17-hidroxi-17 -(1-propinil)estra-4,9-dien-3-ona.
MX2009000950A 2006-08-08 2007-08-06 Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos. MX2009000950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06118587 2006-08-08
PCT/EP2007/058134 WO2008017658A2 (en) 2006-08-08 2007-08-06 Use of glucocorticoid receptor antagonists for treatment of infectious conditions

Publications (1)

Publication Number Publication Date
MX2009000950A true MX2009000950A (es) 2009-02-04

Family

ID=37600754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000950A MX2009000950A (es) 2006-08-08 2007-08-06 Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.

Country Status (13)

Country Link
US (1) US20100075936A1 (es)
EP (2) EP2204171A1 (es)
JP (1) JP2010500323A (es)
KR (1) KR20090039775A (es)
CN (1) CN101500547A (es)
AR (1) AR062229A1 (es)
AU (1) AU2007283604A1 (es)
CA (1) CA2658016A1 (es)
IL (1) IL196392A0 (es)
MX (1) MX2009000950A (es)
TW (1) TW200820977A (es)
WO (1) WO2008017658A2 (es)
ZA (1) ZA200900242B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364146B1 (en) 2008-11-07 2019-06-19 University of Sheffield Medicament and method of diagnosis
EP3434274A1 (en) * 2011-03-31 2019-01-30 Pop Test Oncology LLC Prevention of infection
US20120263660A1 (en) * 2011-04-18 2012-10-18 Pop Test Cortisol Llc Hair Loss Treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP3400233A4 (en) * 2015-08-03 2020-02-26 Pop Test Oncology LLC PHARMACEUTICAL COMPOSITIONS AND METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
ES2092958B1 (es) * 1995-01-10 1997-08-01 Miret Lab Procedimiento para la sintesis de tensioactivos cationicos derivados de la condensacion de acidos grasos con aminoacidos de caracter basico esterificados y su aplicacion como agentes antimicrobianos.
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
CA2250874A1 (en) * 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
US6329534B1 (en) 1999-09-01 2001-12-11 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
US8388986B2 (en) * 2001-08-09 2013-03-05 Laboratorios Miret S.A. Use of cationic surfactants in cosmetic preparations
BR0116522B1 (pt) * 2001-10-25 2013-12-17 Uso de conservantes catiônicos em produtos alimentícios, produtos alimentícios e métodos de conservação de produtos alimentícios
WO2003045363A2 (en) * 2001-11-30 2003-06-05 Solvay Pharmaceuticals Gmbh Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
NZ548374A (en) * 2004-01-09 2010-05-28 Corcept Therapeutics Inc Azadecalin glucocorticoid receptor modulators
JP4797326B2 (ja) * 2004-01-27 2011-10-19 大正製薬株式会社 生薬含有組成物

Also Published As

Publication number Publication date
KR20090039775A (ko) 2009-04-22
IL196392A0 (en) 2009-09-22
AR062229A1 (es) 2008-10-22
CA2658016A1 (en) 2008-02-14
US20100075936A1 (en) 2010-03-25
ZA200900242B (en) 2011-06-29
TW200820977A (en) 2008-05-16
JP2010500323A (ja) 2010-01-07
AU2007283604A1 (en) 2008-02-14
WO2008017658A2 (en) 2008-02-14
WO2008017658A3 (en) 2008-04-10
EP2051705A2 (en) 2009-04-29
CN101500547A (zh) 2009-08-05
EP2204171A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
MX2009000950A (es) Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.
NZ602698A (en) Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
EP1800685A4 (en) PHARMACEUTICAL COMPOSITION BASED ON STEROID SAPONINS, PROCESS FOR PREPARING THE SAME AND USE THEREOF
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
MX2013006070A (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
NO20056153L (no) Preparat omfattende antiprogestiner og rene antiostrogener for profylakse og behandling av hormon-avhengige sykdommer
PT1421099E (pt) Esteres de 17-alfa, 21-di-hidroxipregneno como agentes anti-androgenicos
BR0214643A (pt) Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
TW200612962A (en) Estriol and estetrol prodrugs
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
CA2459033A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
ATE500834T1 (de) Kontrazeptivum
GEP20135792B (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and use of the same
DK1910398T3 (da) 17-alfa-substituerede derivater af estradiol med sårhelende virkning
ECSP10010152A (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
WO2002101014A3 (en) A process for making estra-4,9(10)-diene steroids
TW200705638A (en) Electrostatic discharge device with controllable holding current

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: POP TEST CORTISOL LLC

FA Abandonment or withdrawal